Agios Pharmaceuticals, INC Form 4 insider transactions

Jay Backstrom, a Director at Agios Pharmaceuticals, Inc., reported a transaction involving restricted stock units and common stock.

AGIOS PHARMACEUTICALS, INC. reports a transaction where Chief Medical Officer Sarah Gheuens sold shares to cover tax obligations related to restricted stock units.

Agios Pharmaceuticals Director Catherine Owen acquired 1,976 restricted stock units on June 13, 2026, as part of a vesting schedule.

Agios Pharmaceuticals Director Jeffrey D. Capello acquired 1,976 shares of common stock through restricted stock units, increasing his beneficial ownership.

Agios Pharmaceuticals Chief Legal Officer James William Burns reported a transaction involving the sale of common stock to cover tax withholding obligations related to vested performance share units.

AGIOS PHARMACEUTICALS, INC. reports a Form 4 filing detailing a transaction by Chief Medical Officer Sarah Gheuens, involving the sale of shares to cover tax obligations following the achievement of a regulatory milestone.

Cecilia Jones, Chief Financial Officer of Agios Pharmaceuticals, Inc., reported transactions involving common stock and performance share units.

Agios Pharmaceuticals Chief Commercial Officer Tsveta Milanova acquired 8,500 shares via performance share unit vesting and sold 3,262 shares to cover tax obligations.

Krishnan Viswanadhan, Chief Corp Dev & Strategy at Agios Pharmaceuticals, reported the vesting of performance share units and a subsequent sale to cover tax obligations.

Agios Pharmaceuticals CEO Brian Goff acquired shares through performance unit vesting and sold a portion to cover tax obligations.

Agios Pharmaceuticals' Principal Accounting Officer, Theodore James Jr. Washburn, disclosed a planned future sale of 5,272 common stock shares under a Rule 10b5-1 trading plan.

Agios Pharmaceuticals CEO Brian Goff reported the acquisition of new equity awards and the sale of shares to cover tax obligations related to vested performance share units.

Agios Pharmaceuticals CFO Cecilia Jones reported multiple equity transactions, including the acquisition of common stock through RSU vesting and subsequent sales to cover tax obligations, alongside new RSU and stock option grants.

Agios Pharmaceuticals' Chief Corporate Development & Strategy, Krishnan Viswanadhan, was granted 14,000 restricted stock units and 52,000 stock options.

Agios Pharmaceuticals' Chief Commercial Officer, Tsveta Milanova, acquired common stock through RSU vesting and subsequently sold a portion to cover tax obligations.

Agios Pharmaceuticals' Chief Legal Officer, James William Burns, sold 2,932 shares of common stock to cover tax obligations following the vesting of 6,000 performance share units.

Agios Pharmaceuticals CEO Brian Goff's performance share units vested following the achievement of key regulatory milestones, leading to routine tax-related share sales.

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, vested 6,000 performance share units and subsequently sold 2,932 shares to cover tax obligations following a regulatory milestone achievement.

Agios Pharmaceuticals' Chief Commercial Officer, Tsveta Milanova, sold shares to cover tax obligations following the vesting of performance share units tied to a regulatory milestone.

Agios Pharmaceuticals' CFO, Cecilia Jones, reported the sale of 2,932 common shares to cover tax obligations following the vesting of performance share units tied to a regulatory milestone.

AGIOS Pharmaceuticals Director David Scadden exercised stock options and immediately sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, exercised stock options and subsequently sold a portion of the acquired common stock under a Rule 10b5-1 trading plan.

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, sold 200 shares of common stock for $43.81 per share, following an option exercise, as part of a pre-arranged trading plan.

Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, exercised stock options and subsequently sold 3,302 shares under a pre-arranged Rule 10b5-1 trading plan.

Agios Pharmaceuticals director David Scadden exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

Agios Pharmaceuticals Director David Scadden exercised stock options and subsequently sold an equal number of common shares on September 30, 2025, under a pre-arranged trading plan.

Agios Pharmaceuticals' CFO, Cecilia Jones, reported the acquisition of common stock from RSU vesting and a subsequent sale to cover tax obligations.

Agios Pharmaceuticals' Principal Accounting Officer, Theodore James Jr. Washburn, reported a planned sale of 8,546 shares of common stock for $36.87 per share, effective September 5, 2025.

Agios Pharmaceuticals Director David Scadden will exercise stock options and sell an equal number of common shares on August 27, 2025, under a pre-arranged 10b5-1 trading plan.

Agios Pharmaceuticals Director Rahul Ballal converted 2,302 restricted stock units into common stock, increasing his direct beneficial ownership.